Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges

RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the de...

Full description

Bibliographic Details
Main Authors: John C. Burnett, John J. Rossi, Jiehua Zhou, Ka-To Shum
Format: Article
Language:English
Published: MDPI AG 2013-01-01
Series:Pharmaceuticals
Subjects:
Online Access:http://www.mdpi.com/1424-8247/6/1/85
id doaj-abacb52a869445c0b16083d574fbbc35
record_format Article
spelling doaj-abacb52a869445c0b16083d574fbbc352020-11-25T03:51:37ZengMDPI AGPharmaceuticals1424-82472013-01-01618510710.3390/ph6010085Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and ChallengesJohn C. BurnettJohn J. RossiJiehua ZhouKa-To ShumRNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted.http://www.mdpi.com/1424-8247/6/1/85small interfering (si)RNAnon-viral vectormultifunctional nanoparticletargeting deliverypassive and active targeting
collection DOAJ
language English
format Article
sources DOAJ
author John C. Burnett
John J. Rossi
Jiehua Zhou
Ka-To Shum
spellingShingle John C. Burnett
John J. Rossi
Jiehua Zhou
Ka-To Shum
Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
Pharmaceuticals
small interfering (si)RNA
non-viral vector
multifunctional nanoparticle
targeting delivery
passive and active targeting
author_facet John C. Burnett
John J. Rossi
Jiehua Zhou
Ka-To Shum
author_sort John C. Burnett
title Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
title_short Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
title_full Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
title_fullStr Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
title_full_unstemmed Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges
title_sort nanoparticle-based delivery of rnai therapeutics: progress and challenges
publisher MDPI AG
series Pharmaceuticals
issn 1424-8247
publishDate 2013-01-01
description RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted.
topic small interfering (si)RNA
non-viral vector
multifunctional nanoparticle
targeting delivery
passive and active targeting
url http://www.mdpi.com/1424-8247/6/1/85
work_keys_str_mv AT johncburnett nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges
AT johnjrossi nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges
AT jiehuazhou nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges
AT katoshum nanoparticlebaseddeliveryofrnaitherapeuticsprogressandchallenges
_version_ 1724486535756120064